Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular DTaP combined vaccine
- Development stage
- Unknown
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular DTaP combined vaccine developed by Changchun BCHT Biotechnology is a three-component vaccine designed to prevent diphtheria, tetanus, and pertussis in infants. It contains purified diphtheria toxoid, tetanus toxoid, and three acellular pertussis antigens—pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN)—adsorbed onto an aluminum hydroxide adjuvant. By presenting these antigens to the immune system, the vaccine stimulates the production of specific antibodies and immunological memory against *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*. As of 2025, the vaccine is undergoing Phase III clinical evaluation in China to assess its safety and immunogenicity in infants starting at two months of age.
- Other names
- adsorbed acellular DTaP (three-component) combined vaccineBCHT DTaP vaccine
02
Targets
PRN (Pertactin)TT (Tetanus toxoid)FHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on adsorbed acellular DTaP combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular DTaP combined vaccine.